Research into the use of IL-2 in glioma patients began as early as 1986, and a phase I trial investigating a glioma cell vaccine transfected with a gene encoding IL-4 showed promising clinical responses in patients with HGGs [50]. This evidence concerns the gene IL2 and central nervous system cancer.